Latest results from the STop IMatinib (STIM) trial claim that imatinib could be safely discontinued in a few chronic myeloid leukemia (CML) individuals with long-lasting full molecular response (CMR). (range: 45-80 years). At analysis, 15 individuals were in persistent stage (CP) and 1 affected person is at accelerated stage (AP), and Sokal ratings were lower… Continue reading Latest results from the STop IMatinib (STIM) trial claim that imatinib